Paul spent 17 years at Eli Lilly, where he held roles including ... s mental health blockbusters, Zyprexa and Cymbalta, and helped oversee development of muscarinic cholinergic receptor agonist ...

Eli Lilly is investing more in its home state of Indiana, pumping up to $250 million more into an existing collaboration with ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

The momentum is now with Lilly. Visible Alpha, a data firm, expects its sales of obesity drugs to overtake Novo’s by 2027 ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Eli Lilly and Purdue University announced a $250 million in what the two institutions say is the largest industry-academic partnership in the country.

Despite the broader market's marginal fluctuations amid concerns over tariffs and Fed decisions, Eli Lilly's strong earnings guidance and product development announcements provided a ...

We came across a bullish thesis on Eli Lilly and Company (LLY) on Substack by Kontra. In this article, we will summarize the bulls’ thesis on LLY. Eli Lilly and Company (LLY)'s share was trading ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing ...

A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...

INDIANAPOLIS - Eli ... Lilly’s cardiometabolic and U.S. businesses. Custer, a 16-year veteran at Lilly, has a background in sales and marketing and has played a pivotal role in early development ...